Research on new and better ways to treat cancer. Covers radiotherapy, targeted microdroplets, nerve-injury protection, drug combinations, and tumor models.
Researchers tracked cfDNA levels before, during, and after colorectal cancer surgery, revealing significant increases associated with age, comorbidities, and surgical manipulation. The study suggests that cfDNA could serve as a non-invasive biomarker to monitor patient outcomes and evaluate surgical effectiveness.
Researchers from Tokyo Metropolitan University developed a new dye that strongly absorbs second near-IR radiation, transforming it to heat. This breakthrough enables clearer imaging and better delivery of heat for therapies in deep tissue medicine.
A study analyzing over a million Medicare patients found that those receiving multi-arterial grafts had improved survival compared to single-arterial graft recipients. However, when accounting for unmeasured confounding variables using surgeon preference as an instrumental variable, no difference in long-term survival was observed.
Scientists from Gladstone Institutes developed a new method called RASAM, which made a surprising discovery that large sections of newly formed DNA are hyperaccessible for many hours. This finding holds important implications for basic understanding of biology and the development of new medicines.
Researchers at the University of Florida have identified a crucial link between a gene mutation and immune system signaling in canine hemangiosarcoma, a potentially life-threatening condition. The study findings reveal an important discovery about how this cancer grows and spreads, providing new insights for novel therapies.
Researchers at University of Birmingham have discovered three new protein biomarkers TFF3, LCN2, and CEACAM5 that show strong predictive potential for colorectal cancer. These biomarkers are linked to cell adhesion and inflammation, processes closely associated with cancer development.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
According to UTHealth Houston research, adolescent and young adult men with cancer have a slightly elevated risk of having preterm birth and children with low birth weight. However, the likelihood of live birth was highest for fathers who had thyroid cancer and lowest for those with gastrointestinal cancer.
The EPFL team has developed a deep-learning pipeline called MaSIF to design new proteins that interact with therapeutic targets. They have successfully designed novel protein binders that can recognize and bind to drug-protein complexes, offering potential applications in cell-based therapies and biosensors.
Researchers developed a system to monitor tumor-informed circulating tumor DNA (ctDNA) after comprehensive genomic profiling (CGP), enabling accurate prediction of patient outcomes. The study showed that this approach can be effectively used in conjunction with CGP data to predict cancer relapse and treatment response, improving person...
The Lancet Commission on Clinical Obesity proposes a new model for diagnosing clinical obesity based on objective measures of illness at the individual level. The proposal aims to settle the ongoing dispute around the idea of obesity as a disease, providing a medically coherent framework for diagnosis.
A recent NUS Medicine study found that a molecule called DUSP6 plays a major role in helping colorectal cancer grow, with higher levels linked to poorer prognosis and decreased survival. Researchers suggest blocking DUSP6 could lead to new therapies for CRC treatment.
Lehigh University bioengineering researcher Tomas Gonzalez-Fernandez is exploring how combining CRISPR with biomaterials can improve gene editing's safety and efficacy for therapeutic use. His NSF CAREER award-funded research aims to develop more targeted and controlled therapies for genetic diseases.
This review highlights the transformative capabilities of single-cell and spatial genomics, providing critical insights into disease mechanisms and developing innovative therapies. The technologies enable comprehensive cell atlases, tracing the evolution of sequencing methods and incorporating multi-omics approaches, which significantl...
The National Comprehensive Cancer Network (NCCN) has joined a two-day meeting in Riyadh, Saudi Arabia, to review updated NCCN Clinical Practice Guidelines for the MENA region. The guidelines provide evidence-based expert consensus-driven recommendations for cancer prevention, screening, treatment, and supportive care, tailored for uniq...
A new study found that inhibiting TBK1 increases CAR-T cell activity and makes cancer cells more susceptible to immune cell targeting. The researchers used patient-derived organotypic tumor spheroids (PDOTS) models to investigate the mechanisms of treatment resistance in solid tumors.
A multi-institutional study led by Mayo Clinic researchers has improved the accuracy of genetic testing for BRCA2 variants, enabling precise risk assessments and personalized treatment plans. The findings will aid in identifying patients who may benefit from targeted therapies such as PARP inhibitors.
A University of Cincinnati Cancer Center study identifies microRNA miR-205 as a promising new target to overcome breast cancer treatment resistance and improve outcomes. The research found that boosting levels of miR-205 could block the production of MED1, a protein responsible for treatment resistance, and improve treatment outcomes.
Weill Cornell Medicine has received a $2.3 million CDC grant to enhance care coordination for young breast cancer survivors, focusing on racially and socio-economically diverse groups to reduce symptom burden and improve survival outcomes.
The study found that COVID-19-related disruptions led to frequent delays in investigations or treatments for children with brain tumors. Caregivers reported feeling traumatized by their experiences, including lack of access to healthcare facilities and social situations, which made it harder to evaluate their concerns.
A new study by Katherine Alexander and Shelley Berger has found a possible source of variability in cancer treatment response in clear cell renal cell carcinoma (ccRCC). The researchers identified two distinct patterns of nuclear speckles in kidney tumors, which may correlate with patient outcomes.
Researchers at KAIST have developed a technology that can treat colon cancer by converting cancer cells into normal-like cells. The breakthrough involves creating a digital twin of the gene network associated with normal cell differentiation, leading to significant promise for reversible cancer therapies.
A new photosensitizer, Ce6-GFFY, is synthesized and demonstrates enhanced anti-tumor immune responses in mouse models. Effective against primary and metastatic tumors, Ce6-GFFY offers a promising therapeutic strategy for colorectal cancer treatment.
Researchers at Texas A&M University have uncovered a mechanism behind cancer progression: the stiffening of tumor cell's environment. This spreading causes increased cell proliferation and tumor growth.
A Norwegian study investigates the relationship between volunteers and patients, revealing that intimate disclosures can create an imbalanced dynamic. The researchers emphasize the importance of maintaining professional boundaries to avoid emotional burnout and ensure effective support.
A novel radiotracer has accurately identified a crucial cancer biomarker, Trop2, found in various types of cancer. The radiotracer, <sup>18</sup> F-AlF-RESCA-T4, enables precise visualization of Trop2 expression and can differentiate lung inflammation from cancer.
The Keck School of Medicine of USC has joined the Ryght Research Network to leverage AI tools and optimize cancer clinical trials. The collaboration aims to offer more clinical trials to patients, build new AI tools, and speed up the development of medical treatments.
The AIRCARE Project will introduce AI-powered systems for real-time diagnosis and precision CO2 laser surgery, improving outcomes for UADT cancer patients. The project aims to reduce positive margins, enhance surgical precision and ease of use, transforming quality of life.
Researchers analyzed individual cells from two craniopharyngioma subtypes to identify specific cell types, their features, and interactions. The study found distinct cell types linked to tumor development and immune response in both adamantinomatous and papillary craniopharyngiomas.
Researchers at Osaka Metropolitan University developed a new technique for head and neck reconstruction that achieves 100% success rate in high-risk patients. The pedicled latissimus dorsi flap technique provides a reliable, fast, and minimally invasive option for complex tissue defects.
Pratyanik Sau, a senior at the University of Texas at Arlington, won an Outstanding Undergraduate Student Oral Presentation Award for his research on graphene using positrons. The study has implications for designing particle accelerators and fusion reactors.
Glioblastoma brain tumors synchronize their growth with the daily release of steroid hormones like cortisol, according to new research. Blocking these signals slows tumor growth and disease progression in animal models.
Researchers developed a deep learning model that classifies pancreatic cancer into molecular subtypes using histopathology images, achieving high accuracy and rapid turnaround time. The AI tool has the potential to improve patient outcomes by enabling timely and tailored treatment strategies.
Women with low-risk ductal carcinoma in situ reported similar experiences undergoing active monitoring versus guideline-concordant care. The study found that both approaches had comparable lived experiences during the 2-year follow-up period.
A randomized study found that active monitoring for low-risk ductal carcinoma in situ did not increase invasive cancer risk compared to guideline-concordant care. Women on active monitoring had comparable rates of disease recurrence and survival.
Five Texas researchers have been honored with the 2025 Edith and Peter O'Donnell Awards for their innovative breakthroughs in small cell lung cancer, lithium-ion battery technology, and galaxy discovery. Lauren Averett Byers is being recognized for her work on novel therapeutic strategies for SCLC, while Caitlin M. Casey is exploring p...
A new DNA sequencing test called AR-ctDETECT has been found to distinguish between patients with poor and favorable prognoses in advanced prostate cancer. The test identified circulating tumor DNA in 59% of patients and showed that detectable ctDNA was associated with worse overall survival.
Researchers at Chung-Ang University have identified a crucial role for specific tRNA fragments in cancer progression, revealing their ability to regulate gene expression and influence tumor growth. The study suggests that these fragments could serve as biomarkers for early-stage cancer detection and targets for therapeutic interventions.
A new treatment shows promise for people with high-risk smoldering multiple myeloma, delaying cancer progression and improving overall survival. Daratumumab significantly reduces risk of progression to active disease and improves patient outcomes.
The American College of Surgeons Geriatric Surgery Verification program significantly decreases hospital stays among older cancer patients, increasing their independence and likelihood of discharge home. The program addresses the unique needs of older adults undergoing major abdominal oncologic procedures.
Omid Veiseh, a Rice University bioengineer, has been elected as a National Academy of Inventors Fellow for his significant contributions to innovation and society's welfare. He holds over 5,000 issued US patents and has demonstrated leadership in biotechnology.
Experts discuss strategies and best practices for sharing accurate, evidence-based health information with patients and caregivers. The event aimed to empower people with cancer to make informed choices about their care.
A new MRI-based imaging technique can rapidly assess ovarian cancer subtypes and their response to treatment, allowing for personalized treatment planning. The technique, called hyperpolarised carbon-13 imaging, distinguishes between two different subtypes of ovarian cancer and reveals their sensitivities to treatment.
Scientists at UCSF have developed engineered T cells that act as immune referees to soothe overreacting immune responses and mope up inflammatory molecules. These cells could improve treatment for organ transplants, type 1 diabetes and other autoimmune conditions by reducing the need for harsh immunosuppressant drugs.
A study published in Nature reveals that dietary fructose promotes tumor growth in animal models of melanoma, breast cancer, and cervical cancer. The liver converts fructose into usable nutrients for cancer cells, a finding that could lead to new treatment avenues.
A series of five papers highlights critical public health challenges related to cancer control in eight SAARC countries and the Rohingya refugee population in Bangladesh. The studies identify barriers contributing to significant disparities in cancer outcomes and actionable solutions to address these challenges.
Researchers found that immunosuppression in prostate cancer is associated with a specialised epithelial subtype. This interaction between the immune system and club-like epithelial cells can lead to treatment resistance in patients with advanced, treatment-resistant prostate cancer.
The Phase Ib/II FELIX trial demonstrated a 76.6% response rate and 55.3% complete remission rate in 127 evaluable patients treated with obe-cel CAR T cell therapy. The median event-free survival was 11.9 months, and the overall survival was 15.6 months.
The ESMO Asia Congress 2024 will focus on multidisciplinary oncology in the Asian region, featuring novel treatment modalities, management of specific cancer types and pan-Asian trials. Key highlights include insights into genetics, biology and practice differences between West and Asia.
The Gustave Roussy Prize recognizes scientists whose work improves cancer treatment and patient outcomes. Established by Pierre Fabre Laboratories, the €200,000 award aims to push boundaries of oncology and offer personalized treatments.
Insilico Medicine has received FDA clearance for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors. ISM5939 demonstrated robust anti-tumor efficacy in preclinical studies and showed favorable safety profiles.
A recent analysis reveals significant gaps in cancer drug cost and availability between high- and low-income countries. Inequities in access to therapy, screening, and healthcare infrastructure contribute to higher cancer incidence and mortality rates in low-income countries.
The conference explores molecular determinants of cancer therapy resistance, a major challenge in the fight against cancer. Researchers discuss new therapeutic approaches and address resistance mechanisms involving tumour cells and the tumour microenvironment.
Researchers have created a method to track genetically modified immune cells using PET scans, providing real-time insights into their behavior and persistence in solid tumors. This technology has the potential to inform personalized treatment options and optimize therapy regimens.
The National Comprehensive Cancer Network (NCCN) is collaborating with leading cancer centers in China to improve cancer treatment and outcomes. NCCN Guidelines provide evidence-based recommendations for cancer treatment, prevention, and supportive care, guiding high-quality care globally.
Researchers at Anglia Ruskin University are investigating the complex relationship between fat tissue and colorectal cancer. The study aims to enhance knowledge of the tumour microenvironment, uncover new molecules crucial for cancer growth, and develop more effective treatments.
Researchers developed a new photoacoustic imaging technique that addresses skin tone bias in breast cancer detection. The technique, combined with specific wavelengths and beamforming methods, enhances target visibility across all skin tones, providing clearer images with improved signal-to-noise ratios.
New research shows that routine symptom screening using a validated tool (SSPedi) can reduce symptom burden and support implementing care pathways for improved symptom management. This study found a clinically meaningful decrease in total symptom score, with 12 of 15 symptoms measured showing significant improvement.
A Chinese Medical Journal study reveals that patients with prostate cancer can undergo surgical removal without a pre-operative biopsy, using a combination of mpMRI and PSMA PET/CT imaging. This approach reduces costs and complications associated with traditional biopsy methods.
The new hospital will provide patient-centered care with personalized, compassionate treatment and groundbreaking research. Patients will have access to top specialists and pioneering therapies in cancer treatment.